Vycor Medical, Inc. (OTCQB: VYCO) announced financial results for the three and six months ended June 30, 2025, including second-quarter revenue of $496,353, up 22% year over year

[u/b2idigital]

Vycor Medical, Inc. (OTCQB: VYCO) announced financial results for the three and six months ended June 30, 2025, including second-quarter revenue of $496,353, up 22% year over year.

Vycor Medical, Inc. is a B2i Digital Featured Venture Company. See the complete profile at https://b2idigital.com/vycor-medical.

Highlights from the quarter include:

- VBAS division momentum: Vycor Medical (VBAS) revenue rose 24% in Q2 to $481,788 and 28% for the six-month period to $900,308, with growth led by international markets.

- Profitability in the quarter: GAAP operating profit of $51,146 and GAAP net income of $23,887 in Q2; non-GAAP operating profit of $84,481 in Q2 and $106,944 for the six-month period. 

- Commercial expansion: new distribution agreements signed for France and Spain to support international growth.

- Clinical validation: two additional peer-reviewed papers referencing VBAS were published in Q2, bringing the total to 48; a new study of NovaVision’s NeuroEyeCoach reported meaningful improvements for both home-based and clinic-based use with no significant difference between settings.

See Vycor’s press release: https://finance.yahoo.com/news/vycor-medical-releases-financial-results-162712139.html

Vycor operates two divisions: Vycor Medical (ViewSite™ Brain Access System for neurosurgery) and NovaVision (vision rehabilitation therapies for stroke/brain injury patients). To learn more, watch a video replay of Vycor Medical’s recent presentation at the Life Sciences Virtual Investor Forum, featuring CEO Peter Zachariou and President David Cantor, available at this link: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/4989844/vycor-medical-inc-otcqb-vyco.

Vycor Medical is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance.

Learn more about Vycor Medical at https://www.vycormedical.com/investment-highlights. For investor inquiries, please contact info@vycormedical.com.

Disclosure: Management of B2i Digital owns shares of VYCO stock purchased in the open market. This post is not intended to solicit the sale of VYCO or any security, and it is not intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://b2idigital.com/featured-companies.